RP-12146 is under clinical development by Rhizen Pharmaceuticals and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RP-12146’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RP-12146 is under development for the treatment of solid tumors (BRCA mutated cancers) including breast, ovarian, fallopian tube, or peritoneal cancer, extensive stage small cell lung cancer (ES-SCLC), metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, bile duct cancer (cholangiocarcinoma), pancreatic, colorectal, gastric and endometrial cancer. The drug candidate is administered through oral route. It acts by targeting poly ADP ribose polymerase1 and poly ADP ribose polymerase2 (PARP 1/2 inhibitor).
Rhizen Pharmaceuticals overview
RhizenPharmaceuticals (RhizenPharma), a subsidiary of Alembic Pharmaceuticals Ltd, is a biopharmaceutical company that discovers and develops small molecule drugs. The company’s research products include c-Met inhibitors, selective P13K inhibitors, CRAC channel inhibitors and GPR 119 agonist. It conducts research in the therapeutic areas of oncology, immune inflammation and metabolic disorders such as diabetes and obesity. RhizenPharma’s products find application in the treatment of diseases such as solid tumors, B cell lymphomas, hematological malignancies, asthma, diabetes and chronic obstructive pulmonary disease, among others. It collaborates with other pharmaceutical companies. Rhizenis headquartered in La Chaux-de-Fonds, Switzerland.
For a complete picture of RP-12146’s drug-specific PTSR and LoA scores, buy the report here.